Recently, the Ministry of Human Resources and Social Security issued a notice to confirm the inclusion of 36 drugs in class B of the Medical Catalog for National Basic Medical Insurance, Occupational Injury Insurance and Maternity Insurance for 2017. Hansoh Pharma’s original new drug in the anti-anaerobic category 1.1, Mailingda (Morinidazole and Sodium Chloride Injection), was included in the Catalog.
Mailingda was Hansoh Pharma’s first innovative drug in category 1.1. The first nitroimidazole anti-infective drug with independent IP, it was included in the list of National Science and Technology Major Projects for “development of important new drugs”. Mailingda was launched on the market in 2014. In 2016, Mailingda became the only winner of the Special Award for Innovative Medicine in Chemical Pharmaceutical Industry in China for 2016.
Mailingda is a third generation nitroimidazole drug. As shown by clinical data, Mailingda features strong antibacterial activity, rapid onset of action, good tolerance and high safety when compared with the previous generations. In addition, there is no need to adjust the administration dosage for patients with slight or moderate hepatic insufficiency, and good efficacy can be achieved for surgical infection and gynecological infection caused by anaerobic bacteria. A solid foundation for market expansion of Mailingda was provided with Hansoh Pharma’s construction of a modern preparation industry park based on EU standards and a quality management approach embracing “full participation, countrywide coverage and continuous improvement”.
The successful launch of Mailingda provided new options for the clinical treatment of anaerobic bacteria, and effectively expanded the scope of drug selection for clinical doctors. For patients, the inclusion of Mailingda in NRDL was no doubt important good news, because it meant they would be able to receive safer and more effective treatment at less treatment cost.
Hansoh Pharma has been deeply engaged in the research of innovative drugs for many years. It has nearly 20 innovative drugs in different research stages in the anti-tumor, psychotropic, internal secretion, digestive tract, cardiovascular and anti-infection fields. With the continuous progress of its innovative drug R&D, the Company is expected to realize great strides in development over the coming years.
